LON:ERGO - Ergomed Share Price, Forecast & News

Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

Ergomed PLC (LON:ERGO) released its quarterly earnings results on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The business earned $22.91 million during the quarter. View Ergomed's Earnings History.

1 equities research analysts have issued 12-month target prices for Ergomed's shares. Their forecasts range from GBX 267 to GBX 267. On average, they expect Ergomed's share price to reach GBX 267 in the next year. This suggests that the stock has a possible downside of 29.2%. View Analyst Price Targets for Ergomed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ergomed.

News headlines about ERGO stock have been trending neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ergomed earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Ergomed.

Some companies that are related to Ergomed include Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Starpharma (SPL), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Biotest (BIO), Bellus Health (BLU), Neptune Wellness Solutions (NEPT), Pfenex (PFNX), Pfenex (PFNX), Rafael (RFL), ProMetic Life Sciences (PLI), Matinas BioPharma (MTNB) and Resverlogix (RVX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), NIO (NIO), Science Applications International (SAIC), Axsome Therapeutics (AXSM), Tilray (TLRY), Celgene (CELG), Carbon Black (CBLK), BioMarin Pharmaceutical (BMRN) and Balchem (BCPC).

Shares of ERGO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of ERGO stock can currently be purchased for approximately GBX 377.

Ergomed has a market capitalization of £178.23 million and generates £63.57 million in revenue each year. Ergomed employs 700 workers across the globe.View Additional Information About Ergomed.

The official website for Ergomed is http://www.ergomedplc.com/.

Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.